Key result
V2O5 nanozymes inhibit platelet aggregation and prevent pulmonary thromboembolism in mice without bleeding.
Why the study?
Because glutathione peroxidase prevents platelet-dependent thrombosis, the authors evaluated antioxidant nanozymes to identify inhibitors of platelet activation and aggregation without bleeding side effects.
Do V2O5 nanozymes inhibit platelet aggregation and prevent pulmonary embolism in mice?
Do V2O5 nanozymes inhibit platelet aggregation and prevent pulmonary embolism in mice?
V2O5 nanozymes demonstrate potential as safe antithrombotic agents by inhibiting platelet aggregation and preventing pulmonary embolism in mice without increasing bleeding risk.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for V2O5 nanozymes as antithrombotics; human trials required before clinical consideration.
Thrombosis is a pathological condition which represents the formation of clots inside blood vessels, blocking the flow of blood through the circulatory system. A high occurrence of thrombotic events, particularly deep vein thrombosis and pulmonary embolism, has been observed in COVID‐19 patients. Platelets (thrombocytes), the small cell fragments in the blood, play crucial roles in vascular haemostasis and thrombosis. The activation and subsequent aggregation of platelets lead to the formation of thrombus, a key process in the development of cardiovascular diseases. Therefore, inhibitors of platelet aggregation are important for the prevention and treatment of many thrombotic disorders. As the selenoenzyme glutathione peroxidase (GPx) is known to prevent platelet‐dependent thrombosis, we have studied a series of antioxidant nanozymes for their ability to inhibit platelet activation/aggregation. Herein, we show that V 2 O 5 nanozymes with specific and morphology‐dependent GPx activity effectively inhibit the aggregation of human platelets and prevent pulmonary thromboembolism in mice. Crucially, the nanozymes do not lead to the unwanted side effect of bleeding, which is important in the development of more effective and safe antithrombotic agents.
No takes yet. Share an insight, caveat, or question.
Sherin et al. (2025) studied Thrombosis and Pulmonary Embolism. V2O5 nanozymes was evaluated on Platelet aggregation and pulmonary thromboembolism. V2O5 nanozymes effectively inhibited human platelet aggregation and prevented pulmonary thromboembolism in mice without causing bleeding side effects.
Synapse has enriched 10 related papers. Consider them for comparative context: